Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

3.71

Mkt cap

12M

Volume

54K

High

3.72

P/E Ratio

-0.08

52-wk high

20.83

Low

3.55

Div yield

N/A

52-wk low

1.80

Laidlaw & Co. analyst Yale Jen has downgraded Cingulate (NASDAQ:CING) from Buy to Hold, indicating a change in the firm's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 22, 2023 | 9:42 am

Maxim Group analyst Naz Rahman has downgraded Cingulate (NASDAQ:CING) from Buy to Hold, indicating a shift in the firm's outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 2:48 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biomerica, Cingulate, Arcutis Biotherapeutics, Panbela Therapeutics, NRX Pharmaceuticals, and Alaunos Therapeutics saw their shares rise by 54.5%, 33.33%, 31.14%, 30.54%, 30.08%, and 29.89% respectively. Conversely, Minerva Surgical, Checkpoint Therapeutics, Structure Therapeutics, Lantheus Holdings, Ainos, and Blue Water Biotech faced declines of 52.5%, 50.31%, 45.24%, 18.8%, 18.08%, and 16.08% respectively.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:07 pm

Maxim Group analyst Naz Rahman has downgraded Cingulate (NASDAQ:CING) from Buy to Hold, indicating a change in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:37 pm

Quanex Building Products Corporation (NYSE:NX) shares dropped by 10.7% to $30.95 after reporting Q4 financial results. Other stocks experienced significant movements in Friday's mid-day session, with notable gainers including Getaround, Inc. (NYSE:GETR), Battalion Oil Corporation (NYSE:BATL), and Bruush Oral Care Inc. (NASDAQ:BRSH), among others. Losers included Chanson International Holding (NASDAQ:CHSN) and Inno Holdings Inc. (NASDAQ:INHD), with significant drops after recent gains or IPO pricing.

Portfolio Pulse from Avi Kapoor

December 15, 2023 | 5:46 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals (VRPX) saw a 57.8% increase, while Verrica Pharmaceuticals (VRCA) rose by 51.06%. ASLAN Pharma (ASLN), Biophytis (BPTS), Context Therapeutics (CNTX), and Immix Biopharma (IMMX) also saw gains. Conversely, Aadi Bioscience (AADI), Aileron Therapeutics (ALRN), Cingulate (CING), Vapotherm (VAPO), SenesTech (SNES), and IN8bio (INAB) experienced declines, with AADI dropping 56.5%.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:31 pm

Cingulate's CFO Louis G. Van Horn retired effective immediately on Dec 13, as per an SEC filing. Shane Schaffer will serve as the interim Principal Financial Officer until a new CFO is appointed.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 2:00 pm

Cingulate Inc. shares have resumed trading, indicating a potential change in the company's status or recent news affecting its stock.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 2:01 pm

Cingulate Inc. announced a 1-for-20 reverse stock split effective November 30, 2023. The split will adjust outstanding shares and securities but won't change shareholder equity percentages, except for rounding fractional shares to whole. The Board had the discretion to choose the ratio, which will not alter the par value or authorized shares. The CUSIP number for the Common Stock will change to 17248W204.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 2:26 pm

Cingulate reported an improvement in its Q3 2023 earnings per share (EPS) to $(0.30) from $(0.36) year-over-year (YoY).

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.